Wide Ranks

IPHA

Innate Pharma S.A.

1.50

Top Statistics
Market Cap 121 M Forward PE 3.33 Revenue Growth -69.30 %
Current Ratio 2.92 Trailing PE 0.0000 Earnings Growth 0.00 %
Profit Margins -100.78 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA -1.81 Enterprise / Revenue 1.93 Price To Sales Trailing12 Months 3.59
Profitability
Profit Margins -100.78 % Operating Margins -213.15 %
Balance Sheet
Total Cash 91 M Total Cash Per Share 1.13 Total Debt 35 M
Total Debt To Equity 123.29 Current Ratio 2.92 Book Value Per Share 0.3560
All Measures
Short Ratio 653.00 % Message Board Id finmb_426137 Fax 33 4 30 30 30 00
Shares Short Prior Month 58785 Return On Equity -0.7859 City Marseille
Uuid 95b2a86c-03b1-3402-a4e5-5bdc8b44e164 Previous Close 1.50 First Trade Date Epoch Utc 1 B
Book Value 0.3560 Beta 0.8680 Total Debt 35 M
Volume 6899 Price To Book 4.21 Fifty Two Week Low 1.29
Total Cash Per Share 1.13 Total Revenue 33 M Shares Short Previous Month Date 1 B
Target Median Price 8.00 Max Age 86400 Recommendation Mean 1.60
Sand P52 Week Change 0.3133 Operating Margins -213.15 % Target Mean Price 7.41
Net Income To Common -34052000 Short Percent Of Float 0.0014 Implied Shares Outstanding 89 M
Trailing Peg Ratio None Last Fiscal Year End 1 B Average Daily Volume10 Day 18210
Average Volume10days 18210 Total Cash 91 M Next Fiscal Year End 1 B
Revenue Per Share 0.4190 Ebitda Margins -106.42 % Trailing PE 0.0000
Date Short Interest 1 B Most Recent Quarter 1 B Regular Market Previous Close 1.50
Target Low Price 2.56 Gmt Off Set Milliseconds -18000000 Fifty Day Average 1.92
Open 1.59 Free Cashflow 13 M Dividend Yield 0.00 %
Return On Assets -0.1376 Time Zone Short Name EST Trailing Eps -0.4400
Day Low 1.50 Address1 117, Avenue de Luminy Shares Outstanding 80 M
Price Hint 4 Target High Price 11.50 Website https://www.innate-pharma.com
52 Week Change -0.3750 Average Volume 10250 Forward Eps 0.4500
Recommendation Key buy Compensation As Of Epoch Date 1 B Quick Ratio 276.30 %
Is_sp_500 False Regular Market Day High 1.59 Profit Margins -100.78 %
Debt To Equity 123.29 Fifty Two Week High 3.15 Day High 1.59
Shares Short 63718 Regular Market Open 1.59 Industry Key biotechnology
Earnings Growth 0.00 % Enterprise To Revenue 1.93 Revenue Growth -69.30 %
Shares Percent Shares Out 0.0008 Operating Cashflow -18057000 Currency USD
Time Zone Full Name America/New_York Market Cap 121 M Is_nasdaq_100 False
Zip 13009 Quote Type EQUITY Industry Biotechnology
Long Name Innate Pharma S.A. Regular Market Day Low 1.50 Held Percent Institutions 0.0050
Current Price 1.50 Address2 BP 30191 Enterprise To Ebitda -1.81
Financial Currency EUR Current Ratio 2.92 Gross Margins -58.77 %
Industry Disp Biotechnology Number Of Analyst Opinions 5 Country France
Float Shares 31 M Two Hundred Day Average 2.28 Enterprise Value 65 M
Price To Sales Trailing12 Months 3.59 Forward PE 3.33 Regular Market Volume 6899
Ebitda -35959000 Exchange NMS
Go to Yahoo Finance Go to Seeking Alpha 
Innate Pharma S.

A.

, a biotechnology company, develops immunotherapies for cancer patients in France and internationally.

The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH6401, an BCMA-targeting NK cell engager; and IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager.

Its products in preclinical trials are IPH43, an anti-MICA/B ADC and IPH45, an antibody drug conjugates (ADC); and IPH67, an undisclosed, multi-specific ANKET.

The company has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech; and co-development and license agreement with MedImmune Limited.

Innate Pharma S.

A.

was incorporated in 1999 and is headquartered in Marseille, France.